Your browser doesn't support javascript.
loading
The role of C16:0 ceramide in the development of obesity and type 2 diabetes: CerS6 inhibition as a novel therapeutic approach.
Raichur, Suryaprakash; Brunner, Bodo; Bielohuby, Maximilian; Hansen, Gitte; Pfenninger, Anja; Wang, Bing; Bruning, Jens C; Larsen, Philip Just; Tennagels, Norbert.
Afiliação
  • Raichur S; Evotec International GmbH, Marie-Curie-Strasse 7, 37079 Goettingen, Germany. Electronic address: Surya.Prakash@evotec.com.
  • Brunner B; Sanofi-Aventis Deutschland GmbH, TA Diabetes, Industriepark Höchst, D-65926 Frankfurt am Main, Germany.
  • Bielohuby M; Sanofi-Aventis Deutschland GmbH, TA Diabetes, Industriepark Höchst, D-65926 Frankfurt am Main, Germany.
  • Hansen G; Gubra ApS, Hørsholm Kongevej 11B, 2970 Hørsholm, Denmark.
  • Pfenninger A; Sanofi-Aventis Deutschland GmbH, TA Diabetes, Industriepark Höchst, D-65926 Frankfurt am Main, Germany.
  • Wang B; Analytical Research & Development US Predevelopment Sciences, Sanofi, 153 Second Avenue, Waltham, MA 02451, USA.
  • Bruning JC; Max Planck Institute for Metabolic Research, Gleueler Str. 50, D-50931 Cologne, Germany.
  • Larsen PJ; Grunenthal GmbH, 52072 Aachen, Germany.
  • Tennagels N; Sanofi-Aventis Deutschland GmbH, TA Diabetes, Industriepark Höchst, D-65926 Frankfurt am Main, Germany. Electronic address: Norbert.Tennagels@sanofi.com.
Mol Metab ; 21: 36-50, 2019 03.
Article em En | MEDLINE | ID: mdl-30655217

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ceramidas / Oligonucleotídeos Antissenso / Diabetes Mellitus Tipo 2 / Esfingosina N-Aciltransferase / Obesidade Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ceramidas / Oligonucleotídeos Antissenso / Diabetes Mellitus Tipo 2 / Esfingosina N-Aciltransferase / Obesidade Idioma: En Ano de publicação: 2019 Tipo de documento: Article